Skip to main content

GNS to Provide CombinatoRx with Modeling Software for Drug Studies

NEW YORK (GenomeWeb News) - Gene Network Sciences will use its biological modeling software to assist CombinatoRx in drug efficacy and safety studies, GNS said last week.
 
Under the agreement, the companies will use GNS' reverse engineering/forward simulation software, which it calls REFSTM, to characterize the cellular mechanisms that can cause “synergistic interactions” between multi-target candidate drugs.
 
REFSTM will use data from CombinatoRx’s protein expression and transcriptional profiling studies to create models that simulate both the mechanisms of disease and clinical performance in drug candidates, GNS said.
 
Financial terms of the agreement were not released.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.